8-K: Niagen Bioscience Reports Q1 2026 Results

Niagen Bioscience announced first quarter 2026 financial results, with net sales reaching $31.5 million and net income of $6.3 million.

Summary

• Niagen Bioscience reported first quarter 2026 net sales of $31.5 million, a 3% increase year-over-year. Excluding the divested Analytical Reference Standards and Services segment, net sales grew 5% to $31.1 million.
• Gross margin improved to 63.5%.
• Net income was $6.3 million, which includes a $4.8 million gain from the divestiture of the Analytical Reference Standards and Services segment. Basic and diluted earnings per share were $0.08 and $0.07, respectively.
• Adjusted EBITDA, a non-GAAP measure, was $3.8 million.
• The company ended the quarter with $66.5 million in cash and cash equivalents.
• Niagen Bioscience repurchased $2.4 million of common stock during the quarter.
• The full-year 2026 outlook includes increased sales and marketing investment and an improved general & administrative expense outlook.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, with solid revenue growth and improved margins, despite increased operating expenses and a dip in Adjusted EBITDA, offset by strategic initiatives and a strong cash position.

Positives

• Net sales increased 3% to $31.5 million, with a 5% increase excluding the divested segment.
• Gross margin improved to 63.5%, indicating strength in business mix and supply chain efficiencies.
• Net income of $6.3 million shows year-over-year growth.
• Cash and cash equivalents remain strong at $66.5 million.
• The company successfully launched a clinician-directed telehealth platform under Niagen Plus.
• The first USP monograph for nicotinamide riboside chloride was established, supported by the company's scientific contributions.
• The share repurchase program was increased to $20 million, and $2.4 million of stock was repurchased.
• Expansion of the Niagen Plus clinical channel through a cruise ship clinic partnership.

Negatives

• Operating expenses increased by 26% to $18.4 million, driven by planned investments in brand growth and commercial activities.
• Sales and marketing expenses increased by $1.6 million due to higher advertising and marketing spend.
• General and administrative expenses increased by $2.1 million, partly due to the absence of a prior year credit loss recovery.
• Cash flow from operating activities was a net outflow of $1.2 million, primarily due to increased inventory and timing of receivables.
• Adjusted EBITDA decreased to $3.8 million from $4.9 million in the prior year quarter.

Risks

• The market and size of the vitamin, mineral, and dietary supplement market and the intravenous market.
• Decreased demand for products and services.
• Market acceptance of products.
• Ability to protect intellectual property rights.
• Impact of litigation or infringement actions.
• Competition from other providers and products.
• Risks in product development and ability to develop pharmaceutical business.
• Inability to raise capital to fund continuing operations or new product development.

Future Outlook

The company updated its full-year 2026 outlook, expecting net sales to increase between 10-15% year-over-year (excluding the divested segment), driven by e-commerce and new partnerships. Gross margin is expected to see slight improvement. Sales & marketing investment will increase as a percentage of sales to drive customer acquisition and support new verticals. General & administrative expenses are projected to increase by $3 million to $4 million. Research & development investment will also increase for pharmaceutical development and research initiatives.

Management Comments

• "We delivered $31.5 million of net sales and $6.3 million of net income for the first quarter, said Niagen Bioscience CEO, Rob Fried. Our results reflect continued execution across the business, including growth in our e-commerce channel and progress across key strategic initiatives. We are advancing our scientific leadership and expanding our commercial reach while remaining focused on disciplined investment and long-term value creation from our NAD+ platform."
• Management emphasizes a focus on disciplined investment and long-term value creation from their NAD+ platform.

Industry Context

StockSavvy.ai notes that Niagen Bioscience's focus on NAD+ precursors positions it within the growing healthy aging and cellular metabolism market. The establishment of a USP monograph for nicotinamide riboside chloride is a significant step in standardizing quality and reinforcing the company's leadership in this niche, potentially setting a benchmark for competitors.

Legal Proceedings

• The company has a history of legal settlements, including a past settlement with Elysium Health, LLC, which resulted in a credit loss recovery in Q1 2025.

Stakeholder Impact

• Shareholders: Positive impact from continued revenue growth, improved gross margins, and an increased share repurchase program.
• Employees: Potential impact from increased investment in sales, marketing, and R&D, suggesting growth and development opportunities.
• Customers: Continued availability of Tru Niagen and expanded access through Niagen Plus telehealth and clinic channels.
• Suppliers: Increased inventory levels suggest ongoing demand and potential for sustained orders.

Next Steps

• Continue to invest in sales and marketing to drive customer acquisition and support new verticals.
• Invest in pharmaceutical development and research initiatives.
• Monitor and normalize inventory levels throughout the remainder of the year.
• Continue to expand Niagen Plus channel and product offerings.
• Evaluate market opportunity for topical skincare products.

Key Dates

Recommendation

The company shows steady revenue growth and improved margins, with strategic initiatives like the telehealth platform and USP monograph being positive. However, increased operating expenses and a decrease in Adjusted EBITDA, coupled with the inherent risks in the bioscience sector, warrant a cautious 'hold' recommendation pending further evidence of sustained profitability and growth acceleration.

Keywords

Niagen Bioscience, NAD+, Nicotinamide Riboside, Tru Niagen, Q1 2026 Earnings, Financial Results, Bioscience, Health